Tivic Health Systems, Inc. (TIVC)
NASDAQ: TIVC · Real-Time Price · USD
2.520
-0.040 (-1.56%)
At close: Apr 1, 2025, 4:00 PM
2.500
-0.020 (-0.79%)
After-hours: Apr 1, 2025, 5:17 PM EDT
Tivic Health Systems Revenue
In the year 2024, Tivic Health Systems had annual revenue of $780.00K, down -33.67%. Tivic Health Systems had revenue of $180.00K in the quarter ending December 31, 2024, a decrease of -49.58%.
Revenue (ttm)
$780.00K
Revenue Growth
-33.67%
P/S Ratio
0.94
Revenue / Employee
$111,429
Employees
7
Market Cap
1.56M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TIVC News
- 10 days ago - Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth - Business Wire
- 19 days ago - Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast - Business Wire
- 26 days ago - Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System - Business Wire
- 27 days ago - Tivic Health Systems, Inc. Announces Reverse Stock Split - Business Wire
- 4 weeks ago - Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve - Business Wire
- 5 weeks ago - Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team - Business Wire
- 6 weeks ago - Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma - Business Wire